State Street’s CollPlant Biotechnologies CLGN Stock Holding History

State Street’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-182,266	Closed	-$3.08M	–	4799
2021 Q3	$3.08M	Buy	182,266 +5,776	+3%	+$104K	﹤0.01%	3487
2021 Q2	$3.74M	Buy	+176,490	New	+$2.82M	﹤0.01%	3374

Other funds holding CLGN

IMOV

Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return

State Street's CLGN Position: Q4 2021 in Review

State Street sold out of CollPlant Biotechnologies (CLGN) in Q4 2021, closing a stake of 182,266 shares — an estimated $3.08M sold.

State Street first reported a position in CLGN in Q2 2021 and held it in 2 quarters. The position peaked at $3.74M in Q2 2021. 21 funds tracked by Wall St. Rank hold CLGN as of Q4 2021.

State Street reported no remaining CollPlant Biotechnologies position as of Q4 2021 after selling out during the quarter.
State Street sold 182,266 CollPlant Biotechnologies shares in Q4 2021, an estimated $3.08M.
State Street first reported a position in CollPlant Biotechnologies in Q2 2021 and held it in 2 quarters.
State Street's CollPlant Biotechnologies position peaked at $3.74M in Q2 2021.
21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q4 2021.

Based on State Street's 13F filing for Q4 2021, filed 14 Feb 2022.